On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use Authorization for a 10-ﾵg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.

Pending recommendation from the Centers for Disease Control and Prevention (CDC), 10-ﾵg doses were shipped immediately.